targeting jak2 in patients with mpns
Published 3 weeks ago • 54 plays • Length 0:43Download video MP4
Download video MP3
Similar videos
-
1:03
session highlights: targeting jak2 and calr in mpns
-
2:39
targeting jak2 v617f in mpns with interferon alpha and arsenic trioxide
-
0:59
investigating jak2v617f as a therapeutic target in mpns
-
1:26
the future of jak inhibition for mpns
-
4:31
driver mutations in mpns and their impact on prognosis: jak2, mpl, and calr
-
1:38
considerations when selecting between jak inhibitors for patients with mpns
-
7:03
jak2 v617f vaf as a diagnostic and prognostic marker for polycythemia vera and thrombosis risk
-
1:59:56
mmyprespt2hd2024
-
8:06
findings from arms 6 and 7 of the epcore nhl-2 trial: epcoritamab in newly diagnosed fl
-
1:03
the management of ph all in resource-constrained settings in south america
-
1:51
checkpoint inhibition in the treatment of mpns
-
1:27
driver mutations in mpns
-
1:22
exciting upcoming mpns trials: v617f-targeted jak2 inhibitors and anti-calreticulin antibodies
-
8:31
targeting bcl-2 in mds
-
1:23
unmet needs and areas of investigation in the treatment of pediatric and aya patients with mpns
-
1:24
understanding aberrant signaling pathways to prevent resistance to jak2 inhibitors in mpns
-
2:43
the management of advanced phase mpns
-
2:42
hot topics in mpns: disease-modifying drugs, sequencing jak inhibitors and management of bp-mpns
-
2:37
evidence supporting mrd-guided treatment breaks in mm
-
1:02
mpn disease biology: jak2.v617f causes lymphopenia by blocking lymphopoiesis
-
0:53
investigating the place of jak inhibitors in the treatment of myelofibrosis